We had last week in Lille, France the kick-off meeting for the Sweatpatch project. Our aim is to develop an intelligent sensor for monitoring breast cancer. This collaborative effort includes groups specializing in sensor fabrication, measurement, microdevice development, artificial intelligence programming for data interpretation, and hospitals providing volunteer patients for evaluation.
Our team’s role is to develop functionalized graphene that changes its response upon association with breast cancer markers. These markers are present in the patient’s sweat in parts-per-billion concentrations and must be accurately detected.
ABOUT SWEATPATCH PROJECT
SWEATPATCH consists of a diverse team including 2 universities, 2 engineering academic and research institutes, 3 industrial entities (including an SME and a startup), and 3 preclinical and clinical hospital-based organizations engaged in public research and contract work.
INVN is a leading technology corporation supporting biosensor design, system integration, and medical device certification and marketing.
CTK, an SME NGO, specializes in data analysis, machine learning for MedTech, and software development for health data analysis, supported by the Jozef Stefan Institute (JSI).
Universitat Politècnica de València (UPV) will create nanostructured graphene inks with various functional tags to enhance sensitivity and selectivity for VOC biomarkers, proposing a self-reset sensitive material for multi-family VOC detection.
Centrale Lille Institute (CLI) will develop straintronics solutions for VOC quantification and wireless data transfer, and integrate their components into the final prototype.
The University of Bordeaux Université de Bordeaux (UBx) and Bordeaux INP (UBx-INP) team will leverage resonant microsensors for chemical and biochemical detection.
Neurolane (NEURO), a deep-tech startup, focuses on nanofabrication, nanoelectronics, and communication systems.
The laboratory PRISM of the University of Université de Lille (ULille), Casa Sollievo della Sofferenza (CSS), and Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST) will coordinate preclinical and clinical validation. ULille, in collaboration with Centre Oscar Lambret (COL), has expertise in mass spectrometry VOCs detection, biomarker development, and precision oncology.
